Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Dose Ranging Study in Elective Total Hip Replacement Surgery
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2008-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1090
- Registration Number
- NCT00338897
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Alfuzosin for Treating Acute Urinary Retention
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 156
- Registration Number
- NCT00336921
- Locations
- 🇨🇳
Sanofi-aventis, Beijing, China
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 430
- Registration Number
- NCT00336713
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients
- Conditions
- Hypertension
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2011-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1630
- Registration Number
- NCT00335673
- Locations
- 🇪🇬
Sanofi-Aventis Administrative Office, Cairo, Egypt
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
- Conditions
- Angina UnstableAcute Coronary Disease
- Interventions
- Drug: ClopidogrelDrug: acetylsalicyclic acid (ASA)
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25086
- Registration Number
- NCT00335452
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia
🇪🇸Sanofi-Aventis Admnistrative Office, Madrid, Spain
Lantus Effect on Myocardial Glucose Metabolism in T2
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT00335465
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT00334581
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 508
- Registration Number
- NCT00332891
- Locations
- 🇷🇸
Sanofi-Aventis Administrative Office, Belgrade, Serbia
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
- Conditions
- Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 250
- Registration Number
- NCT00331994
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: Semuloparin sodiumDrug: Enoxaparin sodiumDrug: Placebo (for Enoxaparin sodium)Drug: Placebo (for Semuloparin sodium)
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 705
- Registration Number
- NCT00331838
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey